Vaccine

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment

FREMONT, Calif., Nov. 21, 2024 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated biotechnology company, and nCartes, Inc., a…

1 month ago

Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology

Grant Received from the Bill & Melinda Gates Foundation to Fund Development of Affordable TherapeuticsJUPITER, Fla., Nov. 21, 2024 (GLOBE…

1 month ago

Converge Bio raises $5.5M Seed to speed up drug discovery and development with Generative AI

TEL AVIV, Israel, Nov. 20, 2024 /PRNewswire/ -- Converge Bio, a generative AI platform for accelerated drug discovery and development, today…

1 month ago

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee 

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the…

1 month ago

Bioeconomy Information Sharing and Analysis Center Announces the 2025 Cyberbiosecurity Summit

LAUREL, Md., Nov. 19, 2024 /PRNewswire/ -- Today, the Bioeconomy Information Sharing and Analysis Center (BIO-ISAC), announces the 2025 Cyberbiosecurity Summit…

1 month ago

LINDIS Biotech Signs Licensing Agreement with Pharmanovia for the Commercialization of Catumaxomab

Catumaxomab received a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) at its October 2024…

1 month ago

GHIT Fund Awarded Open Philanthropy Grant to Expand Funding Sources for Global Health R&D

TOKYO, Nov. 18, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund is pleased to announce that Open Philanthropy, a grantmaking…

1 month ago

CBIH Strengthens Clinical Research Team in Preparation for Launch of Next-Generation Cannabinoid Solutions

HOUSTON, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) continues to invest in top-tier talent as…

1 month ago

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting

Poster presentation highlighted results from confirmatory Phase 3 RESILIENT study of TNX-102 SL (sublingual cyclobenzaprine HCl) treatment demonstrating statistically significant…

1 month ago